Clinical Trials Logo

Metastatic Solid Tumor clinical trials

View clinical trials related to Metastatic Solid Tumor.

Filter by:

NCT ID: NCT06235437 Not yet recruiting - Clinical trials for Metastatic Solid Tumor

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.

NCT ID: NCT06171750 Recruiting - Solid Tumor Clinical Trials

Phase I Study of ANK-101 in Advanced Solid Tumors

ANCHOR
Start date: January 19, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of ANK-101 in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in two parts; Part 1 will enroll participants with superficial lesions and Part 2 will enroll participants with visceral lesions.

NCT ID: NCT06163391 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Start date: May 9, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined

NCT ID: NCT06108050 Recruiting - Clinical trials for Advanced Solid Tumor

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

NCT ID: NCT05983523 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

Start date: December 28, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, or other anti-cancer treatment is required, or the Sponsor ends the study, whichever occurs first.

NCT ID: NCT05935098 Recruiting - Solid Tumor Clinical Trials

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Start date: August 21, 2023
Phase: Phase 1
Study type: Interventional

This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.

NCT ID: NCT05919537 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Start date: September 6, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

NCT ID: NCT05898399 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.

NCT ID: NCT05875168 Recruiting - Clinical trials for Advanced Solid Tumor

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Start date: August 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

NCT ID: NCT05872867 Recruiting - Colorectal Cancer Clinical Trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).